- Home
- PLX vs DOMO Comparison
PLX vs DOMO Comparison
Compare PLX & DOMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLX | DOMO |
|---|---|---|
| Founded | 1993 | 2010 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 230.0M | 189.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PLX | DOMO |
|---|---|---|
| Price | $2.97 | $4.23 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 9 |
| Target Price | $12.00 | ★ $13.39 |
| AVG Volume (30 Days) | ★ 1.6M | 1.3M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.29 | $2.29 |
| Revenue Next Year | $16.65 | $2.90 |
| P/E Ratio | $43.14 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.32 | $3.87 |
| 52 Week High | $3.10 | $18.49 |
Technical Indicators
Market Signals| Indicator | PLX | DOMO |
|---|---|---|
| Relative Strength Index (RSI) | 72.63 | 29.82 |
| Support Level | $2.81 | $4.51 |
| Resistance Level | $3.03 | $5.69 |
| Average True Range (ATR) | 0.17 | 0.48 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 93.00 | 14.36 |
Price Performance
Historical ComparisonAbout PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
About DOMO Domo Inc. Class B
Domo Inc provides a cloud-based platform that digitally connects all the data, systems, and people in an organization, giving them access to real-time data and insights and allowing them to manage their business from their smartphones. The company offers a platform to its customers as a subscription-based service. Users receive notifications on any device and immediately act on the invitation, after which the system can write back to the original system of record. The company derives revenue from subscriptions to its cloud-based platform and professional services.